For how we live.
12 articles published between October 29, 2025 and September 22, 2026.
For people whose pancreas cannot make enzymes, replacement therapy is proven in randomised trials. For healthy people with bloating, the flagship study is a single-arm survey of customers who bought the product online.
A 2019 pooling of 12 trials rated peppermint oil safe and effective for IBS, with a number-needed-to-treat of three. The largest, most rigorous trial then missed its primary endpoint against placebo.
The Bristol Stool Form Scale turns an awkward question into a measurable one. Types 3 to 5 are the healthy middle; the shape of your stool tracks how fast it moved through you.
In a 230-patient randomised trial, self-guided app hypnotherapy produced a 33% pain response versus 48% with an in-person therapist and 22% with education — falling short of non-inferiority.
A meta-analysis of 30 randomised trials found fibre supplements work in IBS, with the benefit concentrated in psyllium. Wheat bran was the most-studied type and did not carry the effect.
A network meta-analysis found route of delivery decides everything, and that autologous transplant ranked below placebo. In IBS, 13 trials produced very low certainty of any effect.
Twelve studies in 1,158 IBS patients found gut-directed hypnotherapy improved symptoms, with the firmest results in high-volume and group delivery. The microbiome route is weaker.
Two double-blind crossover studies in people who had put themselves on gluten-free diets failed to reproduce a gluten effect. One found a different wheat carbohydrate did it instead.
Bloating and visible distension are different problems with different mechanisms. The 2025 ESNM/UEG consensus found visceral hypersensitivity, not gas volume, doing most of the work.
A network meta-analysis of 13 randomised trials put the diet ahead of every alternative for IBS symptoms. Its authors note the trials skipped reintroduction and personalisation entirely.
The American College of Gastroenterology suggests a positive diagnostic strategy over a diagnosis of exclusion, with two blood and stool tests doing most of the ruling-out that is actually warranted.
The trial was designed to test non-inferiority against traditional dietary advice. It found superiority instead, with 62% versus 42% achieving a clinical response over six weeks.